Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Trulieve Cannabis Corp C.TRUL

Alternate Symbol(s):  C.TRUL.NT.U | TCNNF

Trulieve Cannabis Corp. is a vertically integrated cannabis company. The Company has established cannabis operations in three hubs: Southeast, Northeast, and Southwest. Its three regional hubs are anchored by market positions in cornerstone states of Florida, Pennsylvania, and Arizona. The Company operates in regulated markets that require knowledge in cultivation, manufacturing, and retail. The Company utilizes various extraction techniques, including critical ethanol extraction, carbon dioxide extraction, hydrocarbon extraction, and mechanical separation. In addition, the Company owns and utilizes carbon dioxide extraction, distillation, purification and manufacturing technology that is used to produce a range of cannabis topicals and vapes featuring cannabinoids. The Company's brands include premium tier brands Avenue, Cultivar Collection, and Muse; mid-tier brands Modern Flower, Alchemy, Momenta, and Sweet Talk, and value tier brands Co2lors, Loveli, Roll One, and Trekkers.


CSE:TRUL - Post by User

Bullboard Posts
Comment by betterbrewon Nov 22, 2018 10:37am
49 Views
Post# 29009574

RE:RE:RE:TRULIEVE Projects $214M Revenue in 2019

RE:RE:RE:TRULIEVE Projects $214M Revenue in 2019i doubt if they can keep up to 4000 new patients per week.

But:  with the current 100,000 patients and say another 50,000 (1000 per week average new patients) each 3.80 per day on treatments that comes out to   150,000 x 3.80 x 350 days 
(must be closed for some holidays) = 199,500,000 in revenue.

160,000 patients gets 214 million in revenue

20 x sales /109 million shares = 39.27 u.s $ per share.. or  52.00 cdn.  
 long ways to go from current pricing  but it all adds up..  probably too low on the number of patients   plus there will be revenue from mass and cal.

 
Bullboard Posts